Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07557290

Comparative Evaluation of Clinical and Radiographic Outcomes of Mustard Gel (Brassica Nigra) and Mineral Trioxide Aggregate (MTA) as Pulpotomy Agents in Deciduous Molars- A Randomized Controlled Trial

The aim of this clinical trial is to compare two materials to treat baby molars with deep cavities. When the cavity is very deep and reaches the nerve of a baby tooth, dentist perform a treatment called "Pulpotomy". This means removing the damaged part of the nerve and placing medicament on healthy part to help tooth heal and stay pain-free until it falls out naturally. The standard medicine used today is Mineral Trioxide Aggregate (MTA) for treating baby molars that have deep cavities. It works well but is expensive and can darken the tooth. The study is testing a new medicine called Mustard Gel , made from black mustard seeds and may help heal the tooth. Mustard has natural healing and germ-fighting properties.This trial will help to compare Mustard Gel with MTA to see if the agent works to treat pulpitis.

Children aged 6-8 years who need a pulpotomy procedure on a baby molar will be selected. During this procedure, infected part of the pulp tissue will be removed and medicament will be placed over the remaining healthy pulp.

Selected participants will be put into one of the two groups by chance:

1. Mustard Gel Group : tooth will be treated with mustard gel after nerve removal 2. MTA Group : tooth will be treated with MTA, the current standard material. All the teeth will be sealed with a permanent filling material.Participants will be treated with both drugs and monitored after about 1 week, 1 month and 3 months to see if the tooth is pain-free and looks healthy on X-ray. The study will help check if Mustard gel is safe and if it causes any side effects.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

6 year–8 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy co-operative children 6-8 years old
  • primary molars with deep cavities and iatrogenic pulp exposure
  • clinically with no sign of spontaneous pain, sinus tract, tenderness to percussion, pathological mobility
  • radiographically with absence of periapical radiolucency, internal/external root resorption, furcal radiolucency
  • hemorrhage at the site of amputation controlled with 5 minutes
  • tooth should be vital with healthy peridontium
  • tooth should be restoreable

Exclusion criteria

  • teeth without permanent successor
  • teeth with history of irreversible pulpitis
  • post amputation unsuccessful hemorrhage control even after 5 minutes
  • radiographic evidence of internal/external root resorption, furcal/periapical pathology
  • patients with drug allergies or systemic diseases
  • clinical signs of spontaneous pain, sinus tract, tenderness to percussion, pathological mobility

Treatment and study plan

Intervention 1: Mustard Gel

Drug

Gel obtained from Brassica nigra (Black Mustard) seeds will be used as pulpotomy medicament in primary molars placed over pulp stumps after coronal pulp amputation. Approximately 1mm of mustard gel will be applied and tooth will be sealed with permanent filling material.

Intervention 2 : Mineral Trioxide Aggregate (MTA)

Drug

MTA will be mixed according to manufacturer's instructions and placed over the pulp stumps to a thickness of 1-2 mm using an amalgam carrier. It will be compressed gently with damp cotton pellet, the restored with glass-ionomer cement.

Primary outcomes

  1. Clinical and Radiographic success rate of Pulpotomy

    Time frame: At 1 week, 1 month, 3 months post treatment.

    The proportion of the teeth treated with pulpotomy that show clinical and radiographic success. Clinical success rate is defined as absence of pain, swelling, abscess or pathological mobility.

    Radiographic success is defined as absence of internal/external root resorption, furcal/periapical radiolucency or widened PDL space.

    assessment will be done using clinical examination and periapical radiographs.

Sponsors and collaborators

Lead sponsor

Dr Nida Farooq

Other

Registry information

Acronym: MG-MTA-RCT2026

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 29, 2026
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.